Subcutaneous Immunoglobulin Therapy for Adult PI | cutaquig®
Time 2022-08-04 13:17:04Web Name: Subcutaneous Immunoglobulin Therapy for Adult PI | cutaquig®
WebSite: http://www.cutaquigus.com
ID:270290
Keywords:
Therapy,Immunoglobulin,Subcutaneous,forDescription:
Skip to contentadults and pediatric patients 2 years of age and older.confident. complete. cutaquig.
Introducing a Subcutaneous Immune Globulin Therapy That Delivers Innovative Service and Support
Learn MoreSafe and effective PI treatment
Zero serious bacterial infections in clinical studies in adults and children.1-3
See the resultsDiscover the
IgCares patient support program
Join the program and explore the unique benefits for cutaquig patients.
Get greater supportTransitioning to
cutaquig?
Making the transition is simple and straightforward to manage.1
Switch nowResources to get started right
Receive guidance on co-pay assistance and reimbursement matters.Learn more
Questions about cutaquig?
Find helpful answers to common questions about cutaquig and PI.Learn more
References:
Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.Kobayashi RH, Mandujano JF, Rehman SM, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]). Immunotherapy. 2021;13(10):813 -824.See the cutaquig full prescribing information for complete boxed warning
Thrombosis may occur with immune globulin products, including cutaquig.
See the cutaquig full prescribing information for complete boxed warning
Thrombosis may occur with immune globulin products, including cutaquig.
Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Indications and Usage
Cutaquig® (Immune Globulin Subcutaneous (Human) – hipp) is a 16.5% immune globulin solution for subcutaneous infusion indicated for the treatment of primary humoral immunodeficiency in patients 2 years of age or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammagloubulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Important Safety Information
Contraindications
Cutaquig is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Severe hypersensitivity reactions may occur with cutaquig, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the cutaquig infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions.
Thrombosis may occur following treatment with immune globulin products, including cutaquig. For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Falsely elevated blood glucose readings may occur during and after the infusion of cutaquig with some glucometer and test strip systems. When administering cutaquig, measure blood glucose with a glucose-specific method.
Aseptic meningitis syndrome (AMS) can occur with cutaquig. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae.
Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin, especially those containing sucrose. cutaquig does not contain sucrose. Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure.
Monitor cutaquig recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after cutaquig infusion.
Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions. If transfusion-related acute lung injury is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum.
Cutaquig is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Drug Interactions
After infusion of cutaquig, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological test results, with the potential for misleading interpretation.
Adverse Reactions
The most common adverse reactions (≥ 5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough.
Please see the cutaquig full prescribing information
This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our privacy policy for more details.
TAGS:Therapy Immunoglobulin Subcutaneous for
<<< Thank you for your visit >>>
Websites to related : Roundhouse Aquarium Teaching Cen
FacebookTwitterInstagramGet InvolvedDonate0 ItemsHomeAbout UsOceanographic Teaching Stations, Inc. Roundhouse AquariumAnnual ReportsBoard of Director
Helping learning organisations pSkip to content Menu Who we areWhat we doCase Studies#LearningOutLoudResourcesPodcast#LXDmeetupBlogContact us Menu Who we areWhat we doCase
Textual: IRC for macOSSupport Knowledge Base Textual 7 Textual is the world's most popular applica
Real Estate CMA Software For AgeCloud CMA Powered by Lone Wolf Agents Brokers MLS Reviews
Love FormulaEng | Рус | Fra | Esp | Deu
Home - Phibee Télécom, solutioHomeWho we areProducts and servicesNetwork MapKnowledge base
Woodway Treadmills - PerformanceWelcome to WoodwayFirst select your region then languageSelect a RegionNorth AmericaLatin America / CarribeanEuropeGermanyItalyMiddle East / AfricaAsi
University of California MedicalSkip to content University of California, San Francisco About UCSF Se
DevMeetup | The social network fYou need to enable JavaScript to run this app.
Ideavit - The perfect material flogo
adsHot Websites